Mivacron (Mivacurium Chloride)

Mivacurium chloride, the active ingredient in Mivacron, is a non-depolarizing neuromuscular blocking agent presented as an injection solution for intravenous use. It is employed to facilitate endotracheal intubation and to produce skeletal muscle relaxation during operative procedures. Its rapid onset and short duration make it suitable for short procedures and for use as a bridge to longer‑acting agents.

GNH USA supplies Mivacron as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, surgical centres and anesthesia departments worldwide, with validated quality systems and export certifications.

Mivacron is a non‑depolarizing neuromuscular blocker used in anesthesia to achieve rapid and controlled muscle relaxation.

- Facilitation of endotracheal intubation: provides quick skeletal muscle relaxation to allow safe airway placement. - Muscle relaxation during surgical procedures: maintains paralysis throughout the operation for optimal surgical conditions. - Adjunct for short procedures: short acting profile supports brief surgeries or serves as a bridge to longer‑acting agents.

Mivacron may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Transient flushing or erythema at the injection site. - Mild hypotension due to vasodilation. - Bronchospasm, especially in susceptible individuals. - Tachycardia or transient arrhythmias.

Serious or Rare Side Effects: - Anaphylactic reaction requiring immediate intervention. - Prolonged apnea or respiratory depression. - Severe hypotension leading to cardiovascular collapse. - Life‑threatening cardiac arrhythmias such as ventricular tachycardia.

When using Mivacron, clinicians should observe several safety measures.

- Assess neuromuscular function: monitor train‑of‑four response during administration. - Avoid in patients with known hypersensitivity to mivacurium or related compounds. - Use with caution in individuals with atypical pseudocholinesterase deficiency. - Adjust dosing in severe hepatic or renal impairment. - Monitor cardiovascular status: watch for hypotension and bradycardia. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Mivacron can interact with other agents, requiring attention to avoid enhanced effects.

Major Interactions (Avoid): - Aminoglycoside antibiotics: potentiate neuromuscular blockade. - Lithium: may increase muscle relaxation. - Magnesium sulfate: raises risk of prolonged paralysis. - Succinylcholine: additive effects can cause excessive paralysis.

Moderate Interactions (Monitor Closely): - Inhalational anesthetics: may slightly prolong duration of action. - Volatile agents: can contribute to additive hypotensive effects.